α4Integrins as Therapeutic Targets in Autoimmune Disease
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
In this issue of the Journal, two groups of investigators report on clinical trials of natalizumab, a recombinant monoclonal antibody against α4 integrins, for the treatment of multiple sclerosis1 and Crohn's disease.2 Miller et al. report that a group of patients with multiple sclerosis who received monthly injections of natalizumab had significantly fewer new inflammatory central nervous system lesions than the placebo group (a reduction of approximately 90 percent) and had approximately half as many clinical relapses.1 Ghosh et al. report that patients with Crohn's disease also had an improved response to natalizumab,2 with response and remission rates that . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
Springer, T. A. (1994) · Cell · doi:10.1016/0092-8674(94)90337-9 · Cited by 6,929
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
T-Cell Function and Migration — Two Sides of the Same Coin
von Andrian, U. H., & Mackay, C. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010053431407 · Cited by 1,437
Self-citationA Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., & O'Connor, P. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,242
α4 integrins mediate lymphocyte attachment and rolling under physiologic flow
Berlin, C., Bargatze, R. F., Campbell, J. J., von Andrian, U. H., Szabo, M. C., Hasslen, S. R., Nelson, R. D., Berg, E. L., Erlandsen, S. L., & Butcher, E. C. (1995) · Cell · doi:10.1016/0092-8674(95)90491-3 · Cited by 1,003
Self-citationNatalizumab for Active Crohn's Disease
Ghosh, S., Goldin, E., Gordon, F. H., Malchow, H. A., Rask-Madsen, J., Rutgeerts, P., Vyhnálek, P., Zádorová, Z., Palmer, T., & Donoghue, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020732 · Cited by 808
The integrin VLA-4 supports tethering and rolling in flow on VCAM-1.
Alon, R., Kassner, P. D., Carr, M. W., Finger, E. B., Hemler, M. E., & Springer, T. A. (1995) · The Journal of cell biology · doi:10.1083/jcb.128.6.1243 · Cited by 706
Picarella, D., Hurlbut, P., Rottman, J., Shi, X., Butcher, E., & Ringler, D. J. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.5.2099 · Cited by 362
Cited by
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Rothenberg, M. E., & Hogan, S. P. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090720 · Cited by 1,356
“Indeed, antibodies that block these pathways have recently been approved for other diseases, but their anti-eosinophil activity has yet to be determined (171).”
BackgroundKleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
The anatomical and cellular basis of immune surveillance in the central nervous system
Ransohoff, R. M., & Engelhardt, B. (2012) · Nature Reviews Immunology · doi:10.1038/nri3265 · Cited by 972
Self-citationEosinophilic gastrointestinal disorders (EGID)
Rothenberg, M. E. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.10.047 · Cited by 923
Eosinophils: Biological Properties and Role in Health and Disease
HOGAN, S. P., ROSENBERG, H. F., MOQBEL, R., PHIPPS, S., FOSTER, P. S., LACY, P., KAY, A. B., & ROTHENBERG, M. E. (2008) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.02958.x · Cited by 834
Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Dubé, R., Cohen, A., Steinhart, A. H., Landau, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042982 · Cited by 692
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfova, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.024 · Cited by 614
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Nickoloff, B. J., & Nestle, F. O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422147 · Cited by 544
“nizes VCAM-1, and antibodies against VLA-4 improve multiple sclerosis and Crohn disease (100).”
BackgroundImaging outcomes for neuroprotection and repair in multiple sclerosis trials
Barkhof, F., Calabresi, P. A., Miller, D. H., & Reingold, S. C. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.41 · Cited by 378
Hallmarks of Tissue-Resident Lymphocytes
Fan, X., & Rudensky, A. Y. (2016) · Cell · doi:10.1016/j.cell.2016.02.048 · Cited by 354
Factors controlling permeability of the blood–brain barrier
Almutairi, M. M. A., Gong, C., Xu, Y. G., Chang, Y., & Shi, H. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2050-8 · Cited by 306
Cao, Y., Goods, B. A., Raddassi, K., Nepom, G. T., Kwok, W. W., Love, J. C., & Hafler, D. A. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa8038 · Cited by 295
Role of β7 Integrins in Intestinal Lymphocyte Homing and Retention
Gorfu, G., Rivera-Nieves, J., & Ley, K. (2009) · Current Molecular Medicine · doi:10.2174/156652409789105525 · Cited by 292
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Cohen, A., Bitton, A., Baker, J., Dubé, R., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.06.007 · Cited by 285
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Wyant, T., Fedyk, E., & Abhyankar, B. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw092 · Cited by 284
Natalizumab for Multiple Sclerosis
Ransohoff, R. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmct071462 · Cited by 253
Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS
Flanagan, K., Fitzgerald, K., Baker, J., Regnstrom, K., Gardai, S., Bard, F., Mocci, S., Seto, P., You, M., Larochelle, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040443 · Cited by 134
Duan, H., Xing, S., Luo, Y., Feng, L., Gramaglia, I., Zhang, Y., Lu, D., Zeng, Q., Fan, K., Feng, J., et al. (2013) · Scientific Reports · doi:10.1038/srep01687 · Cited by 59
Metadata
- Authors
- von Andrian, U. H., & Engelhardt, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-01-02
- Volume
- 348
- Issue
- 1
- Pages
- 68-72
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1982947309
- Cited by
- 276
- References
- 17
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.